Telomerase Activity as a Marker For Mobilization Quality

NCT01555359 | Unknown

• 1 other identifier: HCT-TEL-001
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Autologous hematopoietic cell transplantation (HCT) is a treatment strategy used as advanced line therapy for different malignancies, mainly hematological. Its main advantage lies in the ability to provide hematologic and immune rescue after high dose chemotherapy therapy. The first requirement of a successful transplantation is recruitment of sufficient amount of cells. This is achieved by mobilizing CD34+ stem cells from the bone marrow to the peripheral blood, by G-CSF priming, and then harvesting the cells from the peripheral blood at the right timing by means of apheresis. Currently, the decision on the optimal collection timing is based on the pre-collection CD34 cells blood concentrations. The investigators goal is to investigate whether telomerase, the telomere elongation enzyme, which constitutionally and solely expressed in progenitor cells, is correlated with collection and post HCT engraftment characteristics. The investigators will collect blood from patients when starting GCSF and on the day of planned apheresis. Pearson correlation test will be used to correlate between telomerase activity in the samples and with collection and engraftment characteristics.

Conditions

Lymphoma; Multiple Myeloma

Study Arms (1)

Patients undergoing stem cell collection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing stem cell mobilization and collection

You may qualify if:

• Age \>18 years
• Patient is candidate for stem cell mobilization and collection
• Patient is willing to sign an informed concent

You may not qualify if:

• Age \<18 years
• Patient not willing or not in a state to sign an informed concent
• Pregnant women

Sponsors & Collaborators

• Rabin Medical Center: lead

Study Sites (1)

BMT Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital

Petah Tikva, 49100, Israel

RECRUITING

Related Publications (1)

• Szyper-Kravitz M, Uziel O, Shapiro H, Radnay J, Katz T, Rowe JM, Lishner M, Lahav M. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol. 2003 Jan;120(2):329-36. doi: 10.1046/j.1365-2141.2003.04043.x.

  PMID: 12542495 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole blood

MeSH Terms

Conditions

Lymphoma; Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders

Study Officials

• Ron Ram, M.D.

  BMT Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ron Ram, M.D.

CONTACT

0504065621; ronra@clalit.org.il

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2012
• First Posted: March 15, 2012
• Study Start: February 1, 2012
• Study Completion: February 1, 2013
• Last Updated: March 15, 2012

Record last verified: 2012-01

Locations

IL (1)